BullBD Old Apps Site
Home
Favorites
Recently viewed Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

BXPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

BXPHARMA 17-Nov-2021

Trading of the shares of the Company will be allowed only in the Spot Market and Block transactions will also be settled as per Spot settlement cycle with cum benefit from 18.11.2021 to 21.11.2021. Trading of the shares of the Company will remain suspended on record date i.e., 22.11.2021.

BXPHARMA 14-Nov-2021

(Cont. of BXPHARMA): other medicines related to the treatment of Covid-19 patients and new products contributed to the attainment of sales growth. The earning per share and operating cash flows per share increased predominantly due to the increase in sales. (end)

BXPHARMA 14-Nov-2021

(Cont. of BXPHARMA): The Company achieved 22.3% increase in sales in the reported first quarter as compared to the same period of prior year. Alongside gaining from the double-digit sales growth consistent to past p increase in sales in the reported first quarter as compared to the same period of prior year. Alongside gaining from the double-digit sales growth consistent to past periods, higher demand for the repurposed drugs for the Covid-19 treatment, (cont.)

BXPHARMA 14-Nov-2021

(Q1 Un-audited): Consolidated EPS was Tk. 3.28 for July-September 2021 as against Tk. 2.41 for July-September 2020; Consolidated NOCFPS was Tk. 4.46 for July-September 2021 as against Tk. 3.00 for July-September 2020. NAV per share was Tk. 86.31 as on September 30, 2021 and Tk. 82.78 as on September 30, 2020. (cont.)

BXPHARMA 07-Nov-2021

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 11, 2021 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended on September 30, 2021.

BXPHARMA 24-Oct-2021

There will be no price limit on the trading of the shares of the Company today (24.10.2021) following its corporate declaration.

BXPHARMA 24-Oct-2021

The Board of Directors has recommended 35% cash dividend for the year ended on June 30, 2021. Date of AGM: 23.12.2021, Time: 10:30 AM, Venue: Digital Platform. Record Date: 22.11.2021. The Company has also reported Consolidated EPS of Tk. 11.49, Consolidated NAV per share of Tk. 83.01 and Consolidated NOCFPS of Tk. 13.50 for the year ended on June 30, 2021 as against Tk. 7.88, Tk. 80.12 and Tk. 13.67 respectively for the same period of the previous year.

BXPHARMA 12-Oct-2021

As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 21, 2021 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended on June 30, 2021.

BXPHARMA 03-Oct-2021

Referring to their earlier news disseminated by DSE on 24.01.2021, 05.09.2021 and 14.09.2021 regarding acquisition of a majority stake in Sanofi Bangladesh Limited, the Company has further informed that they have now completed its acquisition of the majority stake in Sanofi Bangladesh Limited. The final consideration, payable in cash (post the closing adjustments previously outlined), was approximately BDT 469.62 crore (Equivalent pound 39.35 million).

BXPHARMA 14-Sep-2021

(Cont. of BXPHARMA): In the year ended 31 December 2020 (the last audited accounts prepared by Sanofi Bangladesh), Sanofi Bangladesh generated revenue of Taka 3.038 billion (approximately 25.8 million Pound), profit before tax of Taka 277.6 million (approximately 2.35 million Pound) and had gross assets of Taka 6.409 billion (approximately 54.4m Pound). A further announcement will be made in due course to confirm final completion of the Acquisition. (End)

Previous Next page